TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03127072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Description: The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy ± target therapy
Description: chemotherapy ± target therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy ± target therapy
Description: chemotherapy ± target therapy
Study: NCT00852800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: 1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: 1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
Study: NCT03156283

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Plus Activity Monitor
Description: Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
Study: NCT04314674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %3 HS bolus
Description: After head fixation %3 HS bolus 3 ml/kg will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %3 HS infusion 20 ml/h
Description: After head fixation %3 HS 20 ml/h infusion will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% mannitol
Description: After head fixation %20 mannitol 0.6 ml/kg will be administered
Study: NCT02925546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 milled API without SLS and hypermellose (Tablet C)
Description: This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 milled API without SLS and hypermellose (Tablet C)
Description: This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
Study: NCT00284219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation 10Hz
Description: 3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnetic stimulation using a special sham coil
Description: Sham stimulation will be given at the same location as the active, with special sham coil.
Study: NCT04031989

Intervention type: DEVICE
Group type: OTHER
Intervention: CorVista Capture
Description: The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
Study: NCT00583037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Mechanical ventilation controlled by diaphragm electrical activity
Study: NCT02606799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb cytokine elimination
Description: Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
Study: NCT02709603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine butyl bromide
Description: oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo; 2 tablets 30 minutes before the procedure
Study: NCT02384018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stromal cell
Description: Islet transplantation patients will receive autologous MSCs following islets infusion
Study: NCT00959205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARTO 3D
Description: CARTO (3D Electroanatomic imaging)
Study: NCT02925546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 milled API without SLS and hypermellose (Tablet C)
Description: This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
Study: NCT00959205

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Conventional fluoroscopically guided activation mapping
Study: NCT02632357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Study: NCT01229306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation of atrial fibrillation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ablation
Description: Ablation of atrial fibrillation
Study: NCT01659749

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metabolic camp
Description: To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
Study: NCT01885624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAB08
Description: monoclonal antibody
Study: NCT05109923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Herbal Supplement
Description: Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
Study: NCT01939184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3055
Description: 12.5, 25, 50 or 75 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3055
Description: 12.5, 25, 50 or 75 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3055
Description: 12.5, 25, 50 or 75 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3055
Description: 12.5, 25, 50 or 75 mg dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02903498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: UFT 360mg/m2 qd po d1-14, q3w
Study: NCT00940498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (also known as PKI-587)
Description: Intravenous dosing once weekly infusion
Study: NCT04119232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social incentives-based program
Description: Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
Study: NCT01657292

Intervention type: DRUG
Group type: OTHER
Intervention: Oleogel-S10 ointment
Description: Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10 ointment
Description: Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing

Intervention type: DEVICE
Group type: OTHER
Intervention: Octenilin® wound gel
Description: Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octenilin® wound gel
Description: Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
Study: NCT00839644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency chest wall oscillation
Description: Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillatory Positive Expiratory Pressure
Description: Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD&P: Postural drainage and percussion
Description: Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
Study: NCT02187068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered intravenously
Study: NCT01696890

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: integrated follow-up
Description: close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
Study: NCT02425059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
Study: NCT04419220

Intervention type: OTHER
Intervention: Doppler Ultrasound
Description: Flow measurements using Doppler ultrasound
Study: NCT02425059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT01900652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emibetuzumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emibetuzumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered Orally
Study: NCT02045940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
Study: NCT03932760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT Program
Description: UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
Study: NCT00902460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam; CP-690,550 + midazolam
Description: Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 + midazolam; midazolam
Description: Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
Study: NCT00791752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: ascending single doses (start dose 2 mg), oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01574651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to formoterol
Description: Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
Study: NCT00727792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI -Clinical
Description: MRI done is standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Research
Description: MRI includes extra sequences
Study: NCT02774148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Acetaminophen
Description: The patient will receive 1,000mg po Acetaminophen every 8 hours.
Study: NCT02134470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Description: Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
Study: NCT01612130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg of Valeriana officinalis L
Description: A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 100mg
Description: A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
Study: NCT02648568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis plus relaxation
Description: The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
Study: NCT03058900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Drug: Placebo (saline)
Description: One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Weekly methotrexate in maximum tolerable dosis

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Weekly methotrexate in maximum tolerable dosis
Study: NCT00788788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HELIOX
Description: HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HELIOX
Description: HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HELIOX
Description: HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
Study: NCT01005095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
Study: NCT03346200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Tablet
Description: Randomised dose of tamoxifen 1 pill/day for 180 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Tablet
Description: Randomised dose of tamoxifen 1 pill/day for 180 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Tablet
Description: Randomised dose of tamoxifen 1 pill/day for 180 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Oral Tablet
Description: Randomised dose of tamoxifen 1 pill/day for 180 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Tablet
Description: Randomised dose of tamoxifen 1 pill/day for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Randomised dose of tamoxifen 1 pill/day for 180 days
Study: NCT00277784

Intervention type: PROCEDURE
Intervention: Ultrasound examination
Description: one ultrasound examination
Study: NCT02647424

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole 2.5 mg daily from Day 2 to 6

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole 2.5 mg daily from Day 2 to 6

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene
Description: After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene
Description: After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
Study: NCT01064791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (Dose 1) + tacrolimus + standard of care medications
Description: sotrastaurin (100mg bid) + tacrolimus + standard of care medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (Dose 2) + tacrolimus + standard of care medications
Description: sotrastaurin (200mg bid) + tacrolimus + standard of care medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (Dose 3) + tacrolimus + standard of care medications
Description: sotrastaurin (300mg bid) + tacrolimus + standard of care medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid + tacrolimus + standard of care medications
Description: mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
Study: NCT00670800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
Study: NCT04933487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
Study: NCT01428531

Intervention type: DRUG
Intervention: Fondaparinux Sodium